Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has received positive feedback from the FDA for their upcoming Phase III trial, TACTI-004, which will evaluate efti in combination with pembrolizumab and chemotherapy in the treatment of non-small cell lung cancer. The trial aims to enroll about 750 patients and seeks to establish a new standard of care for patients regardless of PD-L1 expression. This marks a significant advancement in the development of Immutep’s immunotherapies for cancer treatment.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
